3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
41
Recurrence
14
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Vomiting
1
Vascular Diseases
1
Paraproteinemias
1
Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Plasma Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Hemostatic Disorders
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Blood Coagulation Disorders
1
Interventions
Rituximab
43
Cyclophosphamide
26
fludarabine
15
ibrutinib
14
Vincristine
11
Prednisone
11
Doxorubicin
11
pirtobrutinib
10
Bendamustine Hydrochloride
10
obinutuzumab
9
polatuzumab vedotin
6
Inotuzumab Ozogamicin
6
tocilizumab
5
pembrolizumab
5
glofitamab
5
Gemcitabine
5
zanubrutinib
4
venetoclax
4
ublituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Antigens, CD19
4
tazemetostat
3
acalabrutinib
3
Everolimus
3
DTRMWXHS-12
3
veltuzumab
2
sepantronium
2
iberdomide
2
denileukin diftitox
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell
×
Calcium Dobesilate
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled